These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38738709)

  • 1. SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma.
    Xu X; Lin J; Wang J; Wang Y; Zhu Y; Wang J; Guo J
    Hum Vaccin Immunother; 2024 Dec; 20(1):2350101. PubMed ID: 38738709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    Cancer Med; 2024 Apr; 13(7):e7113. PubMed ID: 38545824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    Scand J Immunol; 2023 Oct; 98(4):e13304. PubMed ID: 37294700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors.
    Xu X; Wang J; Wang Y; Zhu Y; Wang J; Guo J
    Cell Oncol (Dordr); 2024 Oct; 47(5):1943-1956. PubMed ID: 39222176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    BMC Urol; 2024 Jan; 24(1):8. PubMed ID: 38172737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma.
    Xu X; Zhang S; Wang Y; Zhu Y; Wang J; Guo J
    Cancer Med; 2023 May; 12(9):10512-10525. PubMed ID: 37031459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients.
    Xu X; Wang Y; Hu X; Zhu Y; Wang J; Guo J
    Neoplasia; 2023 Sep; 43():100919. PubMed ID: 37517099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression.
    Xu X; Wang Y; Chen Z; Zhu Y; Wang J; Guo J
    Cancer Res Treat; 2023 Oct; 55(4):1321-1336. PubMed ID: 37024096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expression.
    Xu X; Wang Y; Chen Z; Zhu Y; Wang J; Guo J
    Immunogenetics; 2023 Apr; 75(2):133-143. PubMed ID: 36515717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Annexin A2 on prognosis and sensitivity to immune checkpoint plus tyrosine kinase inhibition in metastatic renal cell carcinoma.
    Wang J; Lin J; Wang J; Wang Y; Zhu Y; Xu X; Guo J
    Discov Oncol; 2024 Mar; 15(1):86. PubMed ID: 38519766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    Urol Oncol; 2023 Jan; 41(1):51.e13-51.e23. PubMed ID: 36328922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
    Chen J; Hu X; Zhao J; Yin X; Zheng L; Guo J; Chen J; Wang Y; Sheng X; Dong H; Liu X; Zhang X; Liang J; Liu H; Yao J; Liu J; Shen Y; Chen Z; He Z; Wang Y; Chen N; Nie L; Zhang M; Pan X; Chen Y; Liu H; Zhang Y; Tang Y; Zhu S; Zhao J; Dai J; Wang Z; Zeng Y; Wang Z; Huang H; Liu Z; Shen P; Zeng H; Sun G
    Clin Cancer Res; 2024 Jun; 30(11):2571-2581. PubMed ID: 38512114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
    Santoni M; Buti S; Myint ZW; Maruzzo M; Iacovelli R; Pichler M; Kopecky J; Kucharz J; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Kopp RM; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Massari F; Seront E; Calabrò F; Pinto A; Berardi R; Zgura A; Mammone G; Ansari J; Atzori F; Chiari R; Bamias A; Caffo O; Procopio G; Sunela K; Bassanelli M; Ortega C; Grillone F; Landmesser J; Milella M; Messina C; Küronya Z; Mosca A; Bhuva D; Santini D; Vau N; Morelli F; Incorvaia L; Rebuzzi SE; Roviello G; Soares A; Bisonni R; Bimbatti D; Zabalza IO; Rizzo A; Mollica V; Sorgentoni G; Monteiro FSM; Battelli N; Bracarda S; Porta C
    Eur Urol Oncol; 2024 Feb; 7(1):102-111. PubMed ID: 37481365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.
    Fitzgerald KN; Duzgol C; Knezevic A; Shapnik N; Kotecha R; Aggen DH; Carlo MI; Shah NJ; Voss MH; Feldman DR; Motzer RJ; Lee CH
    Eur Urol; 2023 Mar; 83(3):195-199. PubMed ID: 36344318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies.
    Stühler V; Herrmann L; Maas M; Walz S; Rausch S; Stenzl A; Bedke J
    World J Urol; 2022 May; 40(5):1175-1183. PubMed ID: 35217885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma.
    Esterberg E; Iyer S; Nagar SP; Davis KL; Tannir NM
    Clin Genitourin Cancer; 2024 Apr; 22(2):115-125.e3. PubMed ID: 37914609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
    Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
    Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients.
    Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
    Cancer Immunol Immunother; 2018 Jan; 67(1):79-87. PubMed ID: 28918459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27.
    Stellato M; Buti S; Maruzzo M; Bassanelli M; Bersanelli M; Napoli MD; Dionese M; Fanelli M; Filippi R; Fotia G; Galli L; Grillone F; Maffezzoli M; Maiorano BA; Nasso C; Rebuzzi SE; Lalli L; Roviello G; Sorarù M; Vincenzi B; Procopio G; Verzoni E
    Clin Genitourin Cancer; 2024 Jun; 22(3):102078. PubMed ID: 38631104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.